Proximity to muscle cells may promote spread of prostate cancer cells, NIH study suggests

by National Institutes of HealthFrom left to right: prostate cancer cells (square) near skeletal (oblong) and smooth (oval) muscle cells respond to Interleukins 4 and 13 (IL4/13) by producing ann

Updated on: March 08,2024

Proximity to muscle cells may promote spread of prostate cancer cells, NIH study suggests

by National Institutes of HealthFrom left to right: prostate cancer cells (square) near skeletal (oblong) and smooth (oval) muscle cells respond to Interleukins 4 and 13 (IL4/13) by producing ann

Updated on:March 08,2024

'Collateral damage' from normal cell function may cause mutations that play a role in cancer

by Wellcome Trust Sanger InstituteSpatial distribution of APOBEC-positive crypts. APOBEC-positive crypts and their surrounding crypts before microdissection with their SBS mutational spectrums. S

Updated on: February 18,2024

'Collateral damage' from normal cell function may cause mutations that play a role in cancer

by Wellcome Trust Sanger InstituteSpatial distribution of APOBEC-positive crypts. APOBEC-positive crypts and their surrounding crypts before microdissection with their SBS mutational spectrums. S

Updated on:February 18,2024

New study uncovers key culprit behind pediatric brain cancer metastasis

byUniversity of Pittsburgha, A heatmap of gene expression in the four MB subgroups (G3, group 4 (G4), SHH and WNT) and in unaffected (normal) tissues. Twofold change; false discovery rate (FDR) 

Updated on: January 12,2024

New study uncovers key culprit behind pediatric brain cancer metastasis

byUniversity of Pittsburgha, A heatmap of gene expression in the four MB subgroups (G3, group 4 (G4), SHH and WNT) and in unaffected (normal) tissues. Twofold change; false discovery rate (FDR) 

Updated on:January 12,2024

Neoadjuvant immunotherapy with relatlimab and nivolumab is safe and effective in stage III melanoma

byUniversity of Texas M. D. Anderson Cancer CenterCredit: CC0 Public DomainGiving the combination of immune checkpoint inhibitors relatlimab and nivolumab to patients with stage III melanoma bef

Updated on: January 13,2024

Neoadjuvant immunotherapy with relatlimab and nivolumab is safe and effective in stage III melanoma

byUniversity of Texas M. D. Anderson Cancer CenterCredit: CC0 Public DomainGiving the combination of immune checkpoint inhibitors relatlimab and nivolumab to patients with stage III melanoma bef

Updated on:January 13,2024

How the scars of demolished brain tumors seed relapse

byLudwig Cancer ResearchGraphical abstract. Credit:Cancer Cell(2024). DOI: 10.1016/j.ccell.2024.08.012A Ludwig Cancer Research study has discovered that recurrent tumors of the aggre

Updated on: September 30,2024

How the scars of demolished brain tumors seed relapse

byLudwig Cancer ResearchGraphical abstract. Credit:Cancer Cell(2024). DOI: 10.1016/j.ccell.2024.08.012A Ludwig Cancer Research study has discovered that recurrent tumors of the aggre

Updated on:September 30,2024

IKZF1 Alterations an Independent Marker of AML Risk

February 2024Leah LawrenceMutatedIKZF1was an independent marker of adverse risk in patients with acute myeloid leukemia (AML), and patients whose AML had these alterations were at higher r

Updated on: February 18,2024

IKZF1 Alterations an Independent Marker of AML Risk

February 2024Leah LawrenceMutatedIKZF1was an independent marker of adverse risk in patients with acute myeloid leukemia (AML), and patients whose AML had these alterations were at higher r

Updated on:February 18,2024

Young cancer survivors in Europe get increased post-cure help

by Anthony King,Horizon: The EU Research & Innovation MagazineCredit: AI-generated imageAs medical advances in oncology enable more patients to beat tumors, greater attention is being paid t

Updated on: February 03,2024

Young cancer survivors in Europe get increased post-cure help

by Anthony King,Horizon: The EU Research & Innovation MagazineCredit: AI-generated imageAs medical advances in oncology enable more patients to beat tumors, greater attention is being paid t

Updated on:February 03,2024

MTAP loss in metastatic breast cancer patients: Genomic landscape

by Impact Journals LLCMechanism of action of MTAP along with downstream effects from its loss. Abbreviations: MTAP: methylthioadenosine phosphorylase; MTR1P: 5-methylthioribose-1-phosphate; ODC: Ornit

Updated on: January 22,2024

MTAP loss in metastatic breast cancer patients: Genomic landscape

by Impact Journals LLCMechanism of action of MTAP along with downstream effects from its loss. Abbreviations: MTAP: methylthioadenosine phosphorylase; MTR1P: 5-methylthioribose-1-phosphate; ODC: Ornit

Updated on:January 22,2024

'Hard to lose' mutations in tumors may predict response to immunotherapy

byJohns Hopkins University School of MedicineThe figure shows the interactions between immune cells (white) and tumor cells harboring persistent mutations (red) in the context of immunotherapy (

Updated on: January 22,2024

'Hard to lose' mutations in tumors may predict response to immunotherapy

byJohns Hopkins University School of MedicineThe figure shows the interactions between immune cells (white) and tumor cells harboring persistent mutations (red) in the context of immunotherapy (

Updated on:January 22,2024

AI in personalized cancer medicine: New therapies require flexible and safe approval conditions

by Viktoria Bosak,Dresden University of TechnologyA perspective on the US and EU regulatory system readiness for AI-enabled personalized drug and cell-based therapies in precision oncology. The

Updated on: March 05,2024

AI in personalized cancer medicine: New therapies require flexible and safe approval conditions

by Viktoria Bosak,Dresden University of TechnologyA perspective on the US and EU regulatory system readiness for AI-enabled personalized drug and cell-based therapies in precision oncology. The

Updated on:March 05,2024

Engineered T cells may be harnessed to kill solid tumor cells

by Tel Aviv UniversityCredit: Tel Aviv UniversityThere is now a multitude of therapies to treat cancer, from chemotherapy and radiation to immunotherapy and small molecule inhibitors. Chemotherap

Updated on: March 01,2024

Engineered T cells may be harnessed to kill solid tumor cells

by Tel Aviv UniversityCredit: Tel Aviv UniversityThere is now a multitude of therapies to treat cancer, from chemotherapy and radiation to immunotherapy and small molecule inhibitors. Chemotherap

Updated on:March 01,2024

New way to target cancer's diversity and evolution

by Institute of Cancer ResearchCredit: CC0 Public DomainScientists have revealed close-up details of a vital molecule involved in the mix and match of genetic information within cells—opening up

Updated on: April 14,2024

New way to target cancer's diversity and evolution

by Institute of Cancer ResearchCredit: CC0 Public DomainScientists have revealed close-up details of a vital molecule involved in the mix and match of genetic information within cells—opening up

Updated on:April 14,2024